Kornimate/medical-research-clean huggingface dataset:
the effect of hydrolyzed casein on energy expenditure and subjective appetite

Conditions: Increased Energy Expenditure; Increased Satiety

Summary: the primary aim is to examine and compare the effects of hydrolyzed casein (hc), intact casein (ic) and intact whey protein (iwp) on diet-induced thermogenesis (dit). furthermore, to study the effects on appetite regulation assessed by subjective appetite sensations, ad libitum energy intake and appetite regulating hormones. whey and casein differ in absorption and digestion rate, with whey being a fast protein and casein being a slow protein. when casein undergoes hydrolysis the absorption and digestion rates approaches the rates of whey. in the present study the importance of absorption rate and amino acid composition, in regards to energy expenditure and appetite regulation, will be examined. hc and ic have identical amino acid composition, but differ in absorption rate, whereas hc and iwp have similar absorption rates, but differ in amino acid composition. we hypothesize that consumption of hc will increase dit and fat oxidation to a greater extend that ic. moreover, that hc and iwp will increase satiety shortly after protein consumption, whereas ic will be more satiating after several hours. the study is a controlled, randomized, 3-arm crossover study. it consists of three visits in a respiratory chamber separated by at least two weeks. 26 healthy, overweight and obese (bmi 27-35 kg/m2) young men will be enrolled and randomized to the order of the three protein supplements (hc, ic or iwp). at each visit protein supplements (containing either hc, ic or iwp) will be served as breakfast, lunch and dinner. respiratory measures will be obtained over 24 hours and appetite will be assessed by visual analogue scales and appetite regulating hormones. furthermore, ad libitum energy intake will be assessed.


Eligibility criteria:
inclusion criteria: * healthy young men and woman * overweight and obese (bmi 27-35 kg/m2) * 18-40 years * women must have a regular menstrual cycle exclusion criteria: * allergic to dairy products or other food components * vegetarians * weight change \>3kg within 2 months prior to start of the study * use of alcohol \>14 drinks/wk * drug abuse * smoking * physically active \>10 hrs/wk * use of over-the-counter or prescription medication that influences body weight, appetite or metabolism * diabetes mellitus * dyslipidemia * diseases, which influence metabolism * donation of blood 3 months prior to start of the study * subjects with a hemoglobin value \< 8 mol/l (measured at screening) * subjects with a blood glucose level \> 6.1 mmol/l (110 mg/dl) (measured at screening) * subjects who are unable to give an informed consent. * pregnant and lactating women

Keywords: respiratory chambers energy expenditure appetite dairy proteins diet induced thermogenesis obesity
the effectiveness of the wim hof method

Conditions: Healthy; Blood Pressure; Cold Exposure; Stress

Summary: the wim hof method is a multi-disciplinary approach to physical and mental well-being combining cold exposure, breathing exercises, and meditation. this study evaluated the effects of a 15-day whm intervention on cardiovascular parameters at rest and during a cold pressor test, as well as on various psychological parameters.

the wim hof method (whm) is a multi-disciplinary approach to physical and mental well-being combining cold exposure, breathing exercises, and meditation. this study evaluated the effects of a 15-day whm intervention on cardiovascular parameters at rest and during a cold pressor test (cpt), as well as on various psychological parameters. 42 participants were randomized into an intervention (ig) and a control (cg) group. throughout the 15-day intervention, the ig performed the whm daily. the intervention followed the guidelines provided by wim hof. the intervention comprised three components: cold water exposure, breathing exercise, and meditation. the participants were instructed to perform the whm daily over the course of 15 days. the participants could choose when to do so throughout the day, however, the components were to be performed in a strict, sequential order: breathing exercises, followed by meditation, and then cold exposure. participants were asked to complete a daily log in which they documented whether they performed the procedure and for how long. altogether, the procedure lasted about 15 minutes. the cg did not receive an intervention throughout the intervention period. before and after the intervention, systolic (sbp) and diastolic blood pressure (dbp), pulse wave velocity (pwv), heart rate (hr), root mean sum of squared distance (rmssd), and standard deviation of intervals between successive heartbeats (sdnn) were assessed at rest and during a cpt. furthermore, perceived stress (pss), positive affect (panas+), negative affect (panas-), and subjective vitality (trait (svst) and state (svss)) was determined.

Eligibility criteria:
inclusion criteria: * being male * no underlying health conditions * not using antihypertensive or other cardiovascular medications * not engaging in regular exercise training * written informed consent exclusion criteria: * having prior experience with any of the components of the intervention (breathing, meditation, or cold exposure)

Keywords: blood pressure hemodynamics heart rate variability perceived stress meditation cold exposure breathing-method
detection rate of sars-cov-2 in male genitourinary system and its impact on male reproductive health.

Conditions: Coronavirus Disease 2019

Summary: this study will evaluate the changes in sexual function, reproductive function and mental health of male patients discharged from the hospital with covid-19, and the impact of sars-cov-2 on male reproductive health and mental health compared with healthy people during the same period. in addition, men's semen examination reports before and after the new coronavirus pneumonia event will be collected and compared to assess the impact of the event on the quality of men's semen. also, this study will test the sars-cov-2 nucleic acid of the urogenital system of male patients discharged with covid-19 to provide evidence for the effect of the new coronavirus on the male reproductive system.

this study will test sars-cov-2 nucleic acids in urine, prostate fluid, and semen of participants with covid-19 at the first follow-up. all participants will be followed up for 1 year. during follow-up, international index of erectile function-5 (iief-5), quality evaluation questionnaire (qeq), symptom list chart-90 (scl-90) questionnaire evaluation and sexual function related examinations (including nocturnal penile tumescence, color duplex ultrasonography, etc. ) and fertility-related examinations (including sex hormones, semen routine examinations, etc.) will be performed to assess the changes in male sexual function, reproductive function and mental health of male patients discharged with covid-19, and the impact of sars-cov-2 on male reproductive and mental health. in addition, collect male semen examination reports from april to december in 2017-2020 to evaluate the impact of new coronavirus pneumonia incidents on male semen quality.

Eligibility criteria:
inclusion criteria: 1. age≥ 18, ≤ 60 years old; 2. have a fixed sex partner and regular sex life; 3. no previous infectious diseases, chronic diseases, tumor history, and male sexual function and fertility diseases; 4. normal erectile function, iief-5 score\> 21 points; 5. have complete clinical information and contact information； 6. understand and sign the informed consent form. exclusion criteria: 1. hypertension, diabetes, coronary heart disease, hyperlipidemia and other chronic diseases； 2. past history of endocrine diseases such as hypopituitarism, hypogonadism, abnormal thyroid function, etc; 3. past history of mumps virus infection; 4. past history of bladder cancer, prostate cancer, brain spine injury, testicular injury, pelvic fracture, urethral injury and history of surgical treatment; 5. severe cardiovascular and cerebrovascular diseases, severe lung diseases, severe hepatitis; 6. past psychological or mental illness; 7. contact information not available.

Keywords: coronavirus disease 2019 male reproductive health mental health
high dose cvvhdf compared to standard dose cvvhdf

Conditions: Acute Renal Failure

Summary: in the last three decades, the mortality associated with acute renal failure (arf) in the icu has remained unchanged at greater than 50%, despite improvements in dialysis technology. the primary objective is to determine whether continuous veno-venous hemodiafiltration (cvvhdf) using an ultrafiltration rate of 35 ml/hr/kg (high dose) leads to a greater reduction in all-cause icu mortality compared to standard cvvhdf using an ultrafiltration rate of 20 ml/hr/kg.

although the worldwide standard for renal replacement therapy is intermittent hemodialysis(ihd), continuous renal replacement therapy (crrt) has emerged as an alternative form of renal replacement therapy in the critical care setting due to its advantages of slow continuous fluid removal, steady acid-base correction, and hemodynamic stability. there are no standard protocols for initiating or administering crrt, and practice patterns vary widely among institutions, with less than 25% of patients with arf in the icu receiving this therapy in the united states. various crrt modalities are available that use diffusion, convection, or a combination of both to obtain adequate solute clearance. however, there is no consensus as to the optimal dialysis modality, adequate dialysis dose, or optimal clearance modality (convection vs. diffusion). clinical trials are needed to determine the optimal method of administering crrt, with respect to modality, dose of dialysis, and time of initiation of therapy. although some studies suggest that a higher dose of dialysis improves survival, there have been no prospective randomized studies comparing the effectiveness of diffusion and convection, combined together, for solute clearance.

Eligibility criteria:
inclusion criteria: * male or female \> or equal to 19 yrs of age * arf defined by at least one of the following: * volume overload from inadequate urine output despite diuretic agents. * oliguria (urine output \< 200 ml/12hrs) despite fluid resuscitation and diuretic administration. * anuria (urine output \< 50 ml/12 hrs). * acute azotemia (bun \> or equal to 80 mg/dl). * acute hyperkalemia not responsive to medication (k+ \> or equal to 6.5mmol/l) * an increase in serum creatinine of \> 2.5 mg/dl from normal values or a sustained rise in serum creatinine of \> or equal to 1 mg/dl over baseline. exclusion criteria * patients with end stage renal disease * patients who have had more than one previous dialysis session for acute or chronic renal failure during the current hospitalization * patient weight greater than 125 kg * patient weight less than 50 kg * pregnancy * prisoner * non-candidacy for continuous renal replacement therapy (crrt) * patient/surrogate refusal

Keywords: cvvhdf dose study
barostim therapy™ in resistant hypertension

Conditions: Hypertension

Summary: the purpose of this registry (nct02880631) is to evaluate the effect of barostim therapy with the barostim neo system in the commercial setting in subjects recently implanted under the ce-marked indication for resistant hypertension.

summary: the cvrx barostim therapy in resistant hypertension registry will be performed with subjects who have been recently implanted with the barostim neo system in accordance with ce-mark approved criteria for resistant hypertension. subjects must be enrolled within 30 days from implant. up to 500 subjects will be enrolled at up to 50 sites. data should be obtained from standard of care measurements taken prior to implant, at enrollment/baseline, and at 3, 6, and 12 months after the device was implanted. after 12 months, data may be obtained in six month intervals for up to three years after implant, at which time each subject will be exited from the registry. eligibility: subjects must sign an ethics committee (ec) approved informed consent form for the registry to participate. subjects can be included in the hypertension registry if they were implanted in the past 30 days and meet the ce-mark approved indications and contraindications for the barostim neo system in the treatment of resistant hypertension. these include: * indications * systolic blood pressure greater than or equal to 140 mmhg, and * resistance to maximally tolerated therapy with a diuretic and two other anti-hypertension medications * contraindications * bilateral carotid bifurcations located above the level of the mandible * baroreflex failure or autonomic neuropathy * uncontrolled, symptomatic cardiac bradyarrhythmias * carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to be greater than 50% * ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation

Eligibility criteria:
inclusion criteria: * has signed an ec approved informed consent form * has been implanted with the barostim neo system in the past 30 days * systolic blood pressure greater than or equal to 140 mmhg, and * resistance to maximally tolerated therapy with a diuretic and two other anti-hypertension medications exclusion criteria: * bilateral carotid bifurcations located above the level of the mandible * baroreflex failure or autonomic neuropathy * uncontrolled, symptomatic cardiac bradyarrhythmias * carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to be greater than 50% * ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation
peer to peer mentoring: facilitating individuals with early inflammatory arthritis to manage their arthritis: peer mentoring program

Conditions: Early Inflammatory Arthritis; Chronic Disease

Summary: inflammatory arthritis (ia) is a major cause of long-term disability. peer support may be a solution to the common problem of delayed treatment. early peer support may result in improved use of therapy, higher self-efficacy, reduced anxiety, and improved coping in the first two years post-diagnosis. the whole intervention study comprises of two parts: the first part involves the development and testing of a peer mentor training initiative, which is called "peer to peer mentoring: facilitating individuals with early inflammatory arthritis to manage their arthritis - peer mentor training". the second part, which is the focus of this study, involves the delivery of a one-on-one peer support intervention from a trained peer mentor to an individual newly diagnosed with eia. the feasibility and acceptability of the program will be determined, as well as the health outcomes following the participation of the program.


Eligibility criteria:
inclusion criteria: 1. have eia disease duration within 6-52 weeks 2. at least 3 swollen joints, assessed by the treating rheumatologist, or positive compression test for the metacarpophalangeal joints or positive compression test for the metatarsophalangeal joints or at least 30 minutes of morning stiffness 3. prescription of a dmard/biologic by the treating rheumatologist 4. ability to speak and understand english without the aid of a secondary support person; and 5. capability to provide informed consent. exclusion criteria: 1. ia disease duration less than 6 weeks or greater than 1 year 2. previous or ongoing dmard or biologic treatment 3. inability to speak or read grade 6 english; and 4. inability to provide informed consent

Keywords: peer support peer mentor self-management early inflammatory arthritis chronic disease
effectiveness of exercise and physical activity in individuals.

Conditions: COVID-19

Summary: the effects of breathing exercises and physical activity counseling applied for 4 weeks on the number of daily steps, dyspnea, pain, fatigue, mood and quality of life in individuals who have just had covid-19 are not yet known. for this reason, it was aimed to investigate in this study.

in the covid-19 pandemic, which deepened the physical inactivity and sedentary lifestyle, the severity and mortality effect of the virus on humans has decreased today. on the other hand, some symptoms may continue to be seen after recovery in individuals who survived covid-19. it is known that regular physical activities increase immunity and quality of life, reduce stress, anxiety and depression, and support the musculoskeletal and cardiovascular systems. this study aimed to search effects of breathing exercises and physical activity counseling on the step counts, dyspnea, pain, fatigue, mood and quality of life in individuals with post-covid-19.

Eligibility criteria:
inclusion criteria: * adult individuals aged 18 and over who volunteered to participate in the research * individuals who can understand and answer surveys * compatible individuals who can perform exercises and have good cooperation. * individuals who were diagnosed with covid-19 (individuals with a positive polymerase chain reaction (pcr) test result, compatible with covid-19 infection as a result of lung x-ray or lung tomography despite negative pcr test results) and discharged after recovery/home quarantine completed exclusion criteria: * individuals newly diagnosed with covid-19, therefore in quarantine at home or receiving treatment in hospital * individuals with suspected covid-19 * pregnant women * individuals with serious psychiatric illness and therefore unable to adapt to exercise sessions * individuals with severe cognitive impairment * individuals with ongoing orthopedic, neurological, cardiovascular disorders and/or problems which are independent of covid-19

Keywords: physical activity dyspnea pain fatigue anxiety depression quality of life
buprenorphine treatment: a safe alternative for opioid dependent pain patients

Conditions: Opioid Use Disorder

Summary: the purpose of this study is to examine whether buprenorphine can be at least as effective as other opioid medications in relieving chronic pain in patients who suffer from dependence on their opioid medications, while patients simultaneously experience progressive decline of pain along with absence of opioid withdrawal symptoms and improved quality of life.

the study will utilize sublingual buprenorphine for the treatment of chronic pain patients with co-occurring opioid dependence. adult male and female chronic pain patients with co-occurring opioid dependence/disorder, being treated at mmc will be enrolled in a home induction procedure. subjects will be switched from their current opioid pain medication to buprenorphine/naloxone to assess whether buprenorphine is at least as effective, if not more effective, as other opioid medications in controlling their pain while simultaneously improving their psychological distress, functional status, and other aspects of patients' lives. we will utilize a home induction procedure, and maintain subjects on this oral medication for a duration of 6 months. during this period

Eligibility criteria:
inclusion criteria: * meets dsm criteria for opioid dependence (or opioid use disorder when dsm 5 is in use) * has received opioid therapy for at least 90 days * has opioid dependence as assessed by a maimonides psychiatrist exclusion criteria: * scheduled for major surgery during study duration * predicted life expectancy \< 1 year * plan to cease habitation in greater new york area within 6 months * risks for buprenorphine outweigh potential benefit, as determined by the pi * lacks sufficient fluency in english to understand the study protocol, answer survey questions or give informed consent * pregnant women

Keywords: opioids dependence buprenorphine pain
ethanol and cannabinoid effects on simulated driving and related cognition: substudy iii

Conditions: Cannabis; Alcohol Effect; Driving Under the Influence of Alcohol and Other Drugs

Summary: the overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.

to study the effects of ethanol clamped at bac 0.04% (equivalent to consuming approximately 2 drinks over 1 hour) and oral dronabinol (10 mg capsule) on driving.

Eligibility criteria:
inclusion criteria: * males or females 21 to 55 years of age (extremes included). * exposed to cannabis at least once. * exposed to alcohol at least once. * able to provide informed consent. exclusion criteria: * cannabis naïve * alcohol naïve * positive pregnancy screen * hearing deficits * sesame oil allergy
robot-assisted gait training for patients with stroke

Conditions: Cerebrovascular Accident

Summary: investigation of the clinical feasibility and efficacy of a newly developed robot-assisted gait training system for stroke survivors. it is anticipated that robot-assisted gait rehabilitation in combination with standard hospital based rehabilitation will achieve significantly better gait outcomes than standard hospital based rehabilitation alone.

stroke is the leading cause of permanent disability in most developed countries world wide with one-third of the surviving patients from stroke fail to regain independent walking ability. robot-assisted gait rehabilitation that is able to deliver high intensity and consistent repeatability in a safe and controlled environment are gaining traction and advocators for its inclusion as part of the routine post-stroke rehabilitation program. however, despite the recent technological advances in the development and design of better robotics, the exact benefit of the robot-assisted therapy over traditional rehabilitation remain sparse and unclear. it is therefore the aim of the proposed project to fulfil this important gap in our clinical knowledge by comparatively investigate the clinical feasibility and efficacy of a recently developed hiwin robotic gait training system (mrg-p100) against the traditional rehabilitation program with an emphasis on the determination of functional recovery and the appropriate gait adaptation of such robotic system for stroke survivors.

Eligibility criteria:
inclusion criteria: 1. between the age of 20-65 years; 2. diagnosis of first, single unilateral cortical-subcortical stroke verified by brain imaging; 3. paresis of a lower limb; 4. inability to walk without aid or device. exclusion criteria: 1. deemed by a physician to be medically unstable; 2. other prior musculoskeletal conditions that affected gait capacity; 3. co-existence of other neurological diseases; 4. cognitive impairments that would impact on the safe participation in the study (mmse\<23) -